Aduro BioTech is a clinical-stage company that focuses on developing technology platforms to stimulate immune responses against cancer. The company's lead product candidate, CRS-207, is currently in Phase IIb clinical trials for the treatment of pancreatic cancer and malignant pleural mesothelioma. Aduro BioTech is dedicated to advancing immuno-oncology treatments with the goal of providing effective and durable therapies for cancer patients.